Does isoniazid target mycolic acid?

Furthermore, INH inhibits the biosynthesis of mycolic acids, which are extremely long fatty acids, specific to mycobacteria and related genera.

What is the target of isoniazid?

The preferred antitubercular drug isoniazid specifically targets a long-chain enoyl-acyl carrier protein reductase (InhA), an enzyme essential for mycolic acid biosynthesis in Mycobacterium tuberculosis.

Does isoniazid inhibit mycolic acid synthesis?

The level of inhibition was not changed by addition of NAD or nicotinamide; thus, INH does not act on mycolic acid synthesis as an NAD antimetabolite. It is proposed that INH may covalently react with an essential component of the mycolic acid synthesis system.

How does isoniazid treat TB?

Isoniazid is used with other medications to treat active tuberculosis (TB) infections. It is also used alone to prevent active TB infections in people who may be infected with the bacteria (people with positive TB skin test). Isoniazid is an antibiotic and works by stopping the growth of bacteria.

What type of antibiotic is isoniazid?

Isoniazid is in a class of medications called antituberculosis agents. It works by killing the bacteria that cause tuberculosis.

Can isoniazid cause hepatitis?

Most cases of INH hepatotoxicity are mild and commonly resolve despite continued therapy with INH; however, a small number of adult patients taking INH develop severe hepatitis that may progress to liver failure and death if the drug is not stopped promptly.

What are the contraindications of isoniazid?

Who should not take ISONIAZID?

  • caloric undernutrition.
  • a type of joint disorder due to excess uric acid in the blood called gout.
  • alcoholism.
  • a painful condition that affects the nerves in the legs and arms called peripheral neuropathy.
  • acute liver failure.
  • recurring liver problems.
  • liver problems.
  • severe liver disease.

Which drug inhibits mycolic acid synthesis?

The drugs shown to inhibit mycolic acid biosynthesis are isoniazid, ethionamide, isoxyl, thiolactomycin, and triclosan. In addition, pyrazinamide was shown to inhibit fatty acid synthase type I which, in turn, provides precursors for fatty acid elongation to long-chain mycolic acids by fatty acid synthase II.